Literature DB >> 11170651

AMP deaminase inhibitors. 5. Design, synthesis, and SAR of a highly potent inhibitor series.

S R Kasibhatla1, B C Bookser, W Xiao, M D Erion.   

Abstract

A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydronaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (24b), represents a 10- to 250-fold enhancement in AMPDA inhibitory potency without loss in the enzyme specificity. The potency of the inhibitor 24b (AMPDA K(i) = 0.002 microM) is 10(5)-fold lower than the Km for the substrate AMP. It represents the most potent nonnucleotide AMPDA inhibitor known.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170651     DOI: 10.1021/jm000355t

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Synthesis and Biochemical Testing of 3-(Carboxyphenylethyl)imidazo[2,1-f][1,2,4]triazines as Inhibitors of AMP Deaminase.

Authors:  Stephen D Lindell; Simon Maechling; Richard L Sabina
Journal:  ACS Med Chem Lett       Date:  2010-06-18       Impact factor: 4.345

2.  Metabolic adaptations to repeated periods of contraction with reduced blood flow in canine skeletal muscle.

Authors:  Alan MacInnes; James A Timmons
Journal:  BMC Physiol       Date:  2005-07-14

Review 3.  AMP deaminase 1 gene polymorphism and heart disease-a genetic association that highlights new treatment.

Authors:  Ryszard T Smolenski; Iwona Rybakowska; Jacek Turyn; Paweł Romaszko; Magdalena Zabielska; Anne Taegtmeyer; Ewa M Słomińska; Krystian K Kaletha; Paul J R Barton
Journal:  Cardiovasc Drugs Ther       Date:  2014-04       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.